Nasdaq GlobeNewswire

White Dog Labs Announces Key Strategic Collaborations

NEW CASTLE, Del., Jan. 23, 2018 (GLOBE NEWSWIRE) -- White Dog Labs (WDL), an emerging biotech company, today laid out its growth strategy by announcing collaborations with Air Liquide and the Center for Aquaculture Technologies Canada (CATC).

AXIM Biotech Announces Successful Completion of Exploratory Meeting with the Dutch Medicines Evaluation Board on MedChew Rx Program for Treatment of Pain and Spasticity in MS Patients

NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), the world leader in cannabinoid research and development, announced today that it has successfully completed an exploratory meeting with the Dutch Medicines Evaluation Board on its MedChew Rx® clinical development program, which utilizes cannabinoid molecules for treatment of patients experiencing pain and spasticity associated with multiple sclerosis (MS).

Data on Novel Humanized Models for Targeted Immunotherapy Development, a CrownBio Conference Talk on January 24th, 2018

 

SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will unveil data supporting use of its cost-effective, humanized drug target models at the Tumor Models Conference in San Francisco tomorrow, Wednesday, January 24th, 2018.

INmune Bio presenting at NobleCon14 on January 29th

LA JOLLA, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- via Network NewsWire – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system to attack their cancer, today announced that company CEO and President RJ Tesi, M.D., will present at NobleCon14, NOBLE Capital Markets’ 14th annual investor conference, at the W Hotel in Fort Lauderdale, Florida, on January 29 at 10:30 a.m. Eastern Standard Time.

Sharps Compliance Reports Fiscal 2018 Second Quarter Results

 

  • Quarterly revenue of $11.1 million increased 15% over the prior year second quarter
  • Retail market billings increased 57% 
  • Professional market billings improved 11%
  • Government and Assisted Living market billings increased 11% and 9%, respectively
  • Unused Medication solutions billings increased 78% 
  • Quarterly earnings of $0.2 million versus a prior year quarterly loss of $0.2 million

Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock

 

WALTHAM, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten registered direct offering of 2,340,430 shares of its common stock at a price of $2.35 per share. In connection with the offering, Histogenics granted the underwriter a 30-day option to purchase up to an additional 351,064 shares of common stock. All of the shares in the offering are being sold by Histogenics. The offering is expected to close on or about January 25, 2018, subject to customary closing conditions. The gross proceeds to Histogenics from this offering are expected to be $5,500,010.50, before deducting underwriting discounts and commissions, and offering expenses payable by Histogenics.  Certain entities affiliated with directors of Histogenics may purchase shares of common stock in the offering at $2.56, today’s closing price of our common stock on The Nasdaq Capital Market.

CORRECTION: CEO, Brady Granier, From BioCorRx® Inc. Discusses Upcoming FDA Meeting on “Stock Day” Podcast; Aims to Fight Opioid Crisis

 

PHOENIX, Jan. 22, 2018 (GLOBE NEWSWIRE) -- The Uptick Newswire “Stock Day” podcast keeps investors up to date on the latest penny stock news by bringing transparency in the micro-cap side of the market. Connect with “Stock Day” and to over 600+ CEO interviews on the OTC, Pink Sheets and micro-cap news from around the world by following Stock Day’s YouTube, Google Play and iTunes. After many recent news announcements from the Company Everett Jolly, CEO and host of “Stock Day”, was honored to have CEO Brady Granier from BioCorRx® Inc. (OTCQB:BICX) (“Company”) back onto the show.

CEO, Brady Grainer, From BioCorRx®Inc. Paves Pathway Towards Possible FDA Approval on “Stock Day” Podcast; Aims to Fight Opioid Crisis

 

PHOENIX, Jan. 22, 2018 (GLOBE NEWSWIRE) -- The Uptick Newswire “Stock Day” podcast keeps investors up to date on the latest penny stock news by bringing transparency in the micro-cap side of the market. Connect with “Stock Day” and to over 600+ CEO interviews on the OTC, Pink Sheets and micro-cap news from around the world by following Stock Day’s YouTube, Google Play and iTunes. After many recent news announcements from the company Everett Jolly, CEO and host of “Stock Day”, was honored to have CEO Brady Grainer from BioCorRx® Inc. (OTCQB:BICX) (“Company”) back onto the show.

Alvogen CEO Robert Wessman speaks exclusively to World Finance about new opportunities in generic pharmaceuticals

LONDON, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Industry disruptor Robert Wessman, the CEO of rapidly growing generic pharmaceuticals company Alvogen, shares his thoughts on the latest market trends in the new edition of World Finance magazine.

Kraig Biocraft Laboratories Creates First Hybrids in New Research Center

ANN ARBOR, Mich., Jan. 19, 2018 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company succeeded in creating a new hybrid transgenic silkworm at its Michigan production facility.  This is the first hybrid silkworm created at the new Michigan facility, which recently opened in October of 2017. 

Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers Symposium

  • Chemotherapy-free, immunotherapeutic combination evaluated
  • 32% Overall response rate in second-line gastric cancer patients
  • Well tolerated in dose escalation and expansion cohorts

EVIO Inc. Announces 438% Revenue Growth for the Fiscal Year Ended September 30, 2017

BEND, Ore., Jan. 18, 2018 (GLOBE NEWSWIRE) -- EVIO, Inc. (OTCQB:EVIO), a leading provider of quality control testing and advisory services to the regulated cannabis industry, announces financial and operating results for the fiscal year ended September 30, 2017.

Cannabis Science Announces an Overwhelming Response to its Groundbreaking Research on the Use of Cannabinoids in the Treatment of Cancers, Already Has More Views Than 91% of the Papers Published in all Frontiers Journals

 

IRVINE, CA, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to report very strong interest among researchers in the Company’s groundbreaking work to investigate the use of cannabinoids in the treatment of cancers. Cannabis Science’s recent, peer-reviewed publication in Frontiers in Oncology, “Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids”, in just a few months, has already been viewed more than 6,500 times, with the article having more views than 91% of the papers published in all Frontiers journals.

Organovo Announces Release Date for Fiscal Third-Quarter 2018 Financial Results

 

SAN DIEGO, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, February 8, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal third-quarter 2018 financial results.  In advance of the call on February 8, 2018, Organovo will issue its fiscal third-quarter 2018 earnings press release, which will be available at http://www.organovo.com.  To participate in the teleconference, callers can dial the following numbers:

Biorasi Opens Japan Office

 

Miami, FL, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Biorasi, a leading full-service global CRO, is pleased to announce today the opening of their new Japanese office, located in Tokyo. This milestone marks Biorasi’s first regional headquarters located in East Asia, and dramatically expands Biorasi’s capabilities to manage trials in Japan and surrounding territories. The new office will become the command center for all East-Asian operations.

Predictive Technology Group Appoints Dr. Gregory A. Prince to Its Scientific Advisory Board

SALT LAKE CITY, Jan. 17, 2018 (GLOBE NEWSWIRE) --

Innovative Humanized Research Strategies for Immuno-Oncology Drug Development, Crown Bioscience Hosts a Live Webinar

 

SAN DIEGO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will host a webinar on Thursday, January 18, 2018 at 10 am EST (3pm BST/UK), presented by renowned immunologist, Dr. Jayant Thatte. Dr. Thatte will review currently available humanized models and describe innovative applications for preclinical immuno-oncology research.

Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris

~ MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder ~

Pivot Continues To Build Technology Portfolio

 

VANCOUVER, British Columbia, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), and its wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), are pleased to provide its shareholders with a Corporate Update.

CORRECTION -- Arzeda Strengthens Board of Directors with Addition of Biotechnology Veteran William Baum

SEATTLE, Jan. 16, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline on December 21, 2017 by Arzeda, we are advised by the company that "OP Fund" in the second paragraph should have read "OS Fund." The corrected release follows: